Subject Index Vol. 50, 2004
Neuropsychobiology January 1, 2004 Nikolas Coupland, Tai-Jui Chen, Terence O'Donnell et al. 1 citation
No Summary
Toshihiko Kinoshita
Department of Neuropsychiatry, Faculty of Medicine, Kansai Medical University, Osaka, Japan.
2 papers in the library · 1 citation · publishing 2004-2024
Papers
Psychedelic renaissance: A renewed focus on the clinical utility of hallucinogens
Psychiatry and Clinical Neurosciences Reports May 16, 2024 Shunichiro Ikeda, Toshihiko Kinoshita
After a period of prohibition following 1960s abuse, clinical research on psychedelics has resumed since the 1990s, revealing rapid and sustained therapeutic effects. Cannabidiol, ketamine, MDMA, and psilocybin show promise for depression and PTSD, with potential benefits for postpartum depression and PMDD. A Phase II trial enrolling 59 patients with moderate to severe MDD found that psilocybin and escitalopram both reduced depression scores at six weeks, with no significant difference in efficacy, though psilocybin improved symptoms within hours and persisted for months. Ketamine's antidepressant effects were first demonstrated in a double-blind, placebo-controlled study with seven subjects.